Buckberg versus Del Nido in isolated aortic valve replacement: a prospective, two-center, randomized trial

Manel Tauron[1,6], Elena Roselló-Díez[1], Christian Muñoz-Guijosa[2], Constanza Fernández-DeVinzenzi[1], José Montiel[1], Sandra Casellas[1], Ángela Irabien-Ortiz[1], Laura Corominas-García[1], César Piedra[1], Ignasi Julià[3], Claudio Fernández[3], Virginia Cegarra[4], Nerea Guadalupe[4], Marta Molina[1], Juan F. Tabilo[1], Carla Gotsens-Asenjo[1], Cristina Sobre[5], Víctor Gomez[5], Elisabet Berastegui[3], Antonino J. Ginel[1]

[1] Cardiac Surgery Department. Hospital de la Santa Creu i Sant Pau (HSCSP). IIB Sant Pau. Universitat Autónoma de Barcelona. Barcelona. Spain.

[2] Cardiac Surgery Department. Hospital Universitario 12 de Octubre. Instituto de investigación i+12. Universidad Complutense de Madrid. Madrid. Spain

[3] Cardiac Surgery Department. Hospital Germans Trias i Pujol. Badalona. Spain.

[4] Anesthesiology Department. HSCSP. Barcelona. Spain.

[5] Division of Perfusion. HSCSP. Barcelona. Spain.

[6] CIBER-CV. ISCIII. Madrid

Corresponding author:

Manel Tauron Ferrer

Cardiac Surgery Department

Hospital de la Santa Creu i Sant Pau. Mas Casanovas 90. 08025. Barcelona. Spain

Phone number:+34 93 556 59 54

e-mail:mtauron@santpau.cat

Clinical registration number: EU-CTR number: 2018-002701-59

Abstract

Objectives: Interest in Del Nido solution is increasing in adult cardiac surgery. This study compared Del Nido with Buckberg cardioplegia in patients undergoing isolated aortic valve replacement.

Methods: A prospective, two-center, randomized trial was conducted from July 2019 to August 2023, with adult patients undergoing first-time isolated aortic valve replacement, and were randomized to receive Buckberg (n=159) or Del Nido (n=152) solution. Primary endpoint was Creatin Kinase and ultrasensitive Troponin T postoperative peak level.

Results: 311 patients were recruited. Total cardioplegia volume was higher in Del Nido group (1000ml vs 374.5ml, p<0.001). No differences were observed in peak Creatine Kinase or Troponin T levels (422 vs. 407 U/L, and 282 vs. 258 ng/L for Buckberg and Del Nido, respectively), or during postoperative days 1–5. After cross clamp removal, patients in Del Nido group showed higher rates of spontaneous rhythm (66.7% vs 43.1%, p<0.001), and less ventricular fibrillation requiring defibrillation (23.6% vs 49.7%, p<0.001). Peak intraoperative glucose levels (128 mg/dl vs. 198 mg/dl, p<0.001) and insulin administration (18.1% vs. 51.0%, p<0.001) were lower in the Del Nido group. No other differences were found.

Conclusion: No differences between Del Nido and Buckberg solutions were detected. Del Nido presents better intraoperative glycemic control, higher spontaneous rhythm, less ventricular fibrillation requiring defibrillation after cross clamp removal, and more comfortable surgical workflow due to less re-dose interruptions.

Keywords: Cardioplegia, myocardial protection, Buckberg solution, Del Nido solution, aortic valve replacement.

Abbreviations and acronyms

BS: Buckberg solution

DNS: Del Nido Solution

AVR: Aortic Valve Replacement

CK: Creatine Kinase MB isoenzyme

TnT: Ultrasensitive Troponin T

CPB: Cardiopulmonary Bypass

LVEDD: Left Ventricle End Diastolic Diameter

LVEF: Left Ventricle Ejection Fraction

AKIN: Acute Kidney Injury Network

INTRODUCTION

Cardioplegia is crucial for myocardial protection during cardiac surgeries requiring heart arrest. At our institutions the Buckberg cardioplegic solution (BS) has long been the standard choice for cardioplegia. Del Nido solution (DNS) was initially developed as a single dose cardioplegic solution for pediatric cardiac surgery(1). It is a calcium-free, potassium rich, non-glucose-based cardioplegia, with an electrolyte composition similar to extracellular fluid(2). Since 2017, DNS has been available at our hospitals and has progressively become the preferred solution for most isolated and combined procedures.

Interest in DNS has been increasing in adult cardiac surgery, and multiple studies have compare its use with blood cold cardioplegia solutions in adult cardiac procedures(3–8). However, most studies are unicentric, include different procedures or have a small number of patients.

This two-center, prospective, randomized trial aims to compare DNS with BS in elective isolated aortic valve replacement (AVR).

PATIENTS AND METHODS

Ethical considerations

The study followed the Declaration of Helsinki and was approved by each site's Ethical Committee and the Spanish Medical and Sanitary Products Agency (April 12, 2019). The coordinating center's Ethical Committee approval code was IIBSP-CAR-2018-71 (March 23, 2019). It was registered in EU-CTR (2018-002701-59) and Clinical Trials (NCT04259515). All patients provided written informed consent before participation.

Patients and methods

Authors declare that this manuscript has been elaborated according the CONSORT 2010 Statement methods(9).

A prospective, two-center, randomized trial comparing Buckberg and Del Nido solutions in isolated aortic valve replacement was designed and conducted in two Spanish hospitals. Eligible patients were over 18 and required first-time isolated AVR surgery. Exclusion criteria included urgent or emergent procedures according to EuroSCORE-II definitions(10), prior cardiac surgery and patients refusing blood transfusions.

Randomization was performed by the members of research team using central, secure, web-based randomization system with concealed allocation (Clinapsis®, Barcelona, Spain). Blocked randomization used blocks of 30 patients. Participants were randomized 1:1 to receive BS or DNS. Participants were blinded to treatment, but the surgical team (surgeons, perfusionists, anaesthesiologists) could not be blinded due to cardioprotection protocol differences.

Surgical technique and cardioplegic solutions

Conventional general anesthesia was used according to each center's standard (see supplementary material). Surgical approach (full sternotomy or partial upper ministernotomy) and prostheses insertion technique were at surgeon's discretion.

DNS and BS were both standardized commercial solutions. BS was administered in a 4:1 blood:cardioplegia ratio, with an induction dose at 4°C after aortic cross-clamp, followed by maintenance doses every 15–20 minutes or when myocardial activity was observed. A warm reperfusion dose was given before cross-clamp removal(11). DNS was administered in a 1:4 blood:cardioplegia ratio, with a single 20 ml/kg (max 1000 ml) dose at 4°C after cross-clamping. An additional 500 ml dose was given if the ischemic period exceeded 90 minutes or when myocardial activity restarted (see supplementary material for detailed cardioplegia administration protocols)

Intraoperative fluid administration, transfusion, insulin administration and inotropes or vasopressors followed the standard clinical practice and protocols of each center.

Endpoints

Creatine Kinase (CK) and ultrasensitive Troponin T (TnT) levels at postoperative day 1 to 5 were determined daily. Primary endpoint was CK and TnT peak postoperative levels. Normal laboratory reference values were 30 to 200 U/L for CK and <13 ng/L for TnT.

Secondary endpoints included biomarker levels from day 1 to 5, cardiopulmonary bypass (CPB) and cross-clamp times, intra or postoperative inotropic support requirements, spontaneous rhythm or need for defibrillation after aortic cross clamp removal, intra and postoperative hemodilution parameters (CPB and postoperative minimum hematocrit levels and need for blood transfusion), intra and postoperative glucose levels and insulin requirements, intraoperative lactate levels, postoperative creatinine levels and dialysis requirements, echocardiographic parameters related to myocardial injury at discharge: left ventricle end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF). Operative mortality defined as death within 30 days post-surgery or discharge, was also analyzed.

Statistical analysis

Initially the trial was designed to be a three-center study and sample size was calculated to detect differences of 30% or greater in Creatine Kinase (CK). With an alpha risk of 0.05, a beta risk of 0.2 and accounting for a 10% participant loss, a total of 388 patients were required (194 patients in each group). At the end of 2021, recruitment process was slower than expected due to the very low number of patients operated during the COVID-19 pandemic, and because one of the centers refuse to participate. At the same time, new papers published after the beginning of our study comparing Del Nido with other cardioplegic solutions(5,6), showed that postoperative biomarker levels were not as high as we expected when we calculated our initial sample size. That is why we recalculate our sample size to detect a 35% or greater difference in postoperative CK levels, with the same alpha and beta risks and the same 10% participant loss. Sample size changed from the initial 388 to 286 patients (143

patients in each group). That sample size change was approved on 2022 by the ethical committee and by the Spanish regulators (see supplementary material for both approval documents).

Numerical variables were described as mean (standard deviation), or median (interquartile range). A Shapiro-Wilk normality test and a Levene's equality of variances test were performed. Univariate analysis was performed with the Student's t-test or Mann-Whitney U-test (if Shapiro-Wilk test rejected normal distribution or Levene test rejected homoscedasticity). Categorical variables were described as number (percentage). Univariate analysis was performed using chi-squared or Fisher's exact test (if cell frequency≤5).

All data were analyzed using Stata/IC 14.2 for Mac (StataCorp College Station, TX).

RESULTS

Between July 2019 and August 2023, 311 patients were enrolled and randomized to receive either BS (159 patients) or DNS (152 patients) (Figure 1). Table 1 shows preoperative characteristics. There were no statistically significant differences between groups. The mean age was 72.9 years in the BS group and 73.4 years in the DNS group, and the mean EuroSCORE-II was 1.25 and 1.35, respectively.

Table 2 presents intraoperative data. Total cardioplegia volume was significantly higher in DNS group (374.5ml vs 1000ml, p<0.001, BS and DNS groups, respectively). The route of cardioplegia administration differed, with retrograde cardioplegia and direct coronary ostia cannulation more common in the BS group (51.7% vs. 0.69% for retrograde, and 49.7% vs. 15.3% for direct ostia cannulation). After cross-clamp removal, DNS group had higher rates of spontaneous rhythm (66.7% vs 43.1%, p<0.001), and less ventricular fibrillation requiring defibrillation (23.6% vs 49.7%, p<0.001). No differences were observed in LVEF, inotropic use or mechanical support for CPB weaning. Cell saver and hemofiltration use were similar. Although minimal intraoperative hematocrit was significantly lower in DNS group (27.2 vs 28.8%, p<0.005), end-of-surgery hematocrit and intraoperative packed red blood cell transfusion did not differ. Peak intraoperative glucose levels were significantly lower in

DNS group (median of 128mg/dl vs 198mg/dl, p<0.001), as was intraoperative insulin administration according to local protocol (18.8% vs 51.0% of patients requiring insulin administration during surgery, p<0.001).

Table 3 summarizes postoperative data. No differences were observed in peak CK and TnT levels (430 vs 414.5U/L, and 284 vs 258ng/L, for BS and DNS groups, respectively). Similarly, biomarker levels from postoperative days 1 to 5 showed no differences (Figure 2). Linear correlation was found between peak CK level and cross-clamp time in both groups, while relation between TnT peak levels and cross-clamp was not linear (Figure 3). There were no differences in postoperative inotropic or mechanical support, nor in renal function, with no differences in renal failure according to Acute Kidney Injury Network criteria (AKIN)(12) or dialysis requirements. Echocardiography at discharge revealed no differences in LVEF and LVEDD. Postoperative transfusion rates were similar (24.84% vs. 21.38% for BS and DNS, respectively), and there were no differences in hematocrit at discharge. No differences were found in operative mortality, ICU, or in-hospital length of stay.

DISCUSSION

Interest in DNS for adult cardiac surgery has increased in recent years. Several retrospective observational studies suggest DNS may offer advantages over traditional blood cardioplegic solutions, and some randomized trials have compared both(5–7,13). This trial aimed to prospectively compare DNS with BS in a two-center randomized study, involving a large population undergoing isolated aortic valve replacement. Our findings indicate that DNS provides comparable myocardial protection to BS and can be used safely.

Some authors suggest that DNS could improve surgical workflow by shortening CPB and cross-clamp times, due to fewer re-dosing cardioplegia interruptions(14–16). A randomized trial by Ucak and Uncu reached the same conclusion(13). Nonetheless, we did not observe statistically significant differences in CPB and cross-clamp times. The typically short duration of aortic valve replacement may reduce the

need for multiple BS doses, diminishing group differences. However, we found significant differences in cardioplegia administration routes. DNS is generally administered as a single antegrade dose, with direct coronary ostia cannulation reserved for significant aortic regurgitation. In contrast, the BS group had higher rates of retrograde and direct ostia cannulation for cardioplegia administration(11). This implies that DNS might simplify the surgical procedure, making it particularly appealing for minimally invasive strategies.

The trial by Ad and colleagues, reported slightly lower troponin levels in the DNS group, though not statistically significant(5). They suggested that the DNS group might experience an earlier peak in troponin levels, a finding also noted by García-Suárez et al. in their recent trial(7). While we did not find statistically significant differences in myocardial injury biomarkers, slightly lower levels of both biomarkers were observed in the DNS group. Troponin T peaked on postoperative day 1 in both groups, whereas CK levels peaked later in the DNS group (postoperative day 2) compared to the BS group (postoperative day 1).

Ad and colleagues, also found a trend towards reduced inotropic support in the DNS group(5), which could not be confirmed by other randomized trials. In our study, there were no differences in inotropic or mechanical support. The similar biomarker levels and lack of differences in inotropic or mechanical support suggest that DNS offers at least equivalent myocardial protection for patients undergoing aortic valve replacement.

Spontaneous rhythm and ventricular fibrillation after cross-clamp removal are classically associated with myocardial protection(17). Consistent with previous studies, we found that more patients in the DNS group returned to spontaneous rhythm, and fewer experienced ventricular fibrillation requiring defibrillation after cross-clamp removal.

Glucose control is a frequently noted advantage of using DNS. As observed in other studies(7,13), we found lower peak intraoperative glucose levels and reduced insulin administration rates in the DNS

group. Intraoperative glycemic control is not a minor issue, as it is linked to surgical site infection. 2017 Centers for Disease Control and Prevention guideline for prevention of surgical site infection, recommended blood glucose target levels below 200mg/dL in patients with or without diabetes (class IA recommendation)(18). In our study, the median peak intraoperative glucose level was 128mg/dL in the DNS group vs 198mg/dL in the BS group. Only 18.8% of patients in DNS group required insulin to maintain target glucose levels, vs 51% in BS group. The improved glycemic control with DNS is a benefit supported by various authors(3,4,7,13,19) though the correlation with reduced surgical site infection rates requires further investigation..

Hemodilution, resulting from the higher cardioplegia volume used with DNS, is a concern, particularly in shorter surgical procedures where fewer blood cardioplegic doses are needed, leading to a lower overall cardioplegia volume. Although we found a statistically significant difference in cardioplegia volume, we only observed a statistically significant difference in the minimum intraoperative hematocrit which favours the BS group (28.8% vs 27.2%). However, no differences were noted in end-of-surgery or discharge hematocrit levels, nor in intra- or postoperative red blood cell transfusion needs. Cell saver was widespread in both groups, and while there was slightly higher, but not statistically significant, use of ultrafiltration in the DNS group, this may account for the observed difference in intraoperative hematocrit recovery.

The impact of cardioplegia on renal function remains controversial. The trial conducted by Sanetra et al. in patients undergoing aortic valve replacement(6) suggest a trend favouring DNS in postoperative creatinine levels, potentially due to the protective effects of lidocaine used in DNS (20,21). Contrarily, other clinical trials have not supported these findings. In our study, no significant differences were observed in peak postoperative creatinine levels. Using AKIN criteria to classify postoperative renal injury, the DNS group showed lower rates of postoperative dialysis or AKIN 3 injury, nonetheless, that trend did not reach statistical significance. Recent trials involving DNS, focus on myocardial protection parameters as the primary endpoint. As suggested by Sanetra and colleagues**,** further research with

renal function parameters as the primary endpoint is needed to confirm or refute any potential protective effects of DNS against postoperative renal injury.

Study limitations

This study has several limitations. First, intraoperative personnel could not be blinded due to different cardioplegia administration protocols. Second, the analysis of multiple secondary outcomes increases the risk of type I errors, and therefore conclusions regarding secondary endpoints should be interpreted with caution. Third, the study lacked a unified treatment protocol across the two participating centers with each following its usual clinical practice, potentially leading to variations in intraoperative and postoperative treatments.

CONCLUSION

No differences were detected when comparing DNS to BS in elective, isolated aortic valve replacement. DNS may offer additional benefits, including better intraoperative glycemic control, higher rates of spontaneous rhythm, reduced ventricular fibrillation requiring defibrillation after cross-clamp removal, and a more efficient surgical workflow with fewer interruptions for re-dosing. Although the total cardioplegia volume was higher with DNS, this did not correlate with an increased need for red blood cell transfusions or lower end-of-surgery or discharge hematocrit levels.

ACKNOWLEDGMENTS: The authors would like to thank all the professionals from the nursing, perfusion, and postoperative care teams at both centers for their assistance in collecting intraoperative and postoperative data essential for conducting this trial.

FUNDING: None

CONFLICT OF INTEREST: none declared

DATA AVAILABILITY: data underlying this article will be shared upon request to the corresponding author.

REFERENCES

1. Del Nido PJ MG. History and use of del Nido cardioplegia solution at Boston Children's Hospital. J Extracorpor Technol. 2012 Sep;44 (3):98–103.
2. Lenoir M, Bouhout I, Jelassi A, Cartier R, Poirier N, El-Hamamsy I, et al. Del Nido cardioplegia versus blood cardioplegia in adult aortic root surgery. J Thorac Cardiovasc Surg. 2021 Aug;162(2):514-522.e2.
3. Mick SL, Robich MP, Houghtaling PL, Gillinov AM, Soltesz EG, Johnston DR, et al. del Nido versus Buckberg cardioplegia in adult isolated valve surgery. J Thorac Cardiovasc Surg. 2015 Feb;149(2):626-636.e5.
4. Li Y, Lin H, Zhao Y, Li Z, Liu D, Wu X, et al. Del Nido Cardioplegia for Myocardial Protection in Adult Cardiac Surgery: A Systematic Review and Meta-Analysis. ASAIO J. 2018 May;64(3):360–7.
5. Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornaresio LM, Fitzgerald D. The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2018 Mar;155(3):1011–8.
6. Sanetra K, Gerber W, Shrestha R, Domaradzki W, Krzych Ł, Zembala M, et al. The del Nido versus cold blood cardioplegia in aortic valve replacement: A randomized trial. J Thorac Cardiovasc Surg. 2020 Jun;159(6):2275-2283.e1.
7. Garcia-Suarez J, Garcia-Fernandez J, Martinez Lopez D, Reques L, Sanz S, Carballo D, et al. Clinical impact of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2023 Nov;166(5):1458–67.
8. Nakai C, Zhang C, Kitahara H, Shults C, Waksman R, .Molina EzequielJ. Outcomes of del Nido cardioplegia after surgical aortic valve replacement and coronary artery bypass grafting. Gen Thorac Cardiovasc Surg. 2023 Sep;71(9):491–7.
9. Schulz KF, Altman DG, Moher D. CCoOrresNpoSndOenRceT 2010 Statement: updated guidelines for reporting parallel group randomised trials. 2010;
10. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012 Apr 1;41(4):734–45.
11. Buckberg GD, Athanasuleas CL. Cardioplegia: solutions or strategies? Eur J Cardiothorac Surg. 2016 Nov;50(5):787–91.
12. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
13. Ucak HA, Uncu H. Comparison of Del Nido and Intermittent Warm Blood Cardioplegia in Coronary Artery Bypass Grafting Surgery. Ann Thorac Cardiovasc Surg. 2019;25(1):39–45.
14. Ota T, Yerebakan H, Neely RC, Mongero L, George I, Takayama H, et al. Short-term outcomes in adult cardiac surgery in the use of del Nido cardioplegia solution. Perfusion. 2016 Jan;31(1):27–33.
15. Willekes H, Parker J, Neill J, Augustin G, Fanning J, Spurlock D, et al. Efficacy of del Nido cardioplegia in adult cardiac procedures with prolonged aortic crossclamp time. J Thorac Cardiovasc Surg. 2024 Mar;167(3):996-1007.e4.
16. Yerebakan H, Sorabella RA, Najjar M, Castillero E, Mongero L, Beck J, et al. Del Nido Cardioplegia can be safely administered in high-risk coronary artery bypass grafting surgery after acute myocardial infarction: a propensity matched comparison. J Cardiothorac Surg. 2014 Dec;9(1):141.
17. Lockerman ZS, Rose DM, Cunningham JN, Lichstein E. Reperfusion ventricular fibrillation during coronary artery bypass operations and its association with postoperative enzyme release. J Thorac Cardiovasc Surg. 1987 Feb;93(2):247–52.
18. Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017 Aug 1;152(8):784.
19. Mongero LB, Tesdahl EA, Stammers AH, Stasko AJ, Weinstein S. Does the Type of Cardioplegia Solution Affect Intraoperative Glucose Levels? A Propensity-Matched Analysis. J

Extracorpor Technol. 2018 Mar;50(1):44–52.
20. Rancan L, Simón C, Marchal-Duval E, Casanova J, Paredes SD, Calvo A, et al. Lidocaine Administration Controls MicroRNAs Alterations Observed After Lung Ischemia–Reperfusion Injury: Anesth Analg. 2016 Dec;123(6):1437–47.
21. Motayagheni N, Phan S, Eshraghi C, Nozari A, Atala A. A Review of Anesthetic Effects on Renal Function: Potential Organ Protection. Am J Nephrol. 2017;46(5):380–9.

Table 1. Patients baseline characteristics

	Buckberg (n=151)	Del Nido (n=144)	p value
Male, n(%)	84 (55.6)	78 (54.1)	.801
Age (y)	72.9 (66.0-77.8)	73.4 (68.4-77.9)	.655
BMI	28.9 (26.0-31.9)	28.3 (25.7-31.2)	.609
BSA (m^2)	1.92 (± 0.24)	1.88 (± 0.19)	.135
Smoking, n(%)	16 (10.6)	21 (14.6)	.301
Hypertension, n(%)	115 (77.2)	97 (67.4)	.073
DM, n(%)	50 (33.1)	40 (27.8)	.320
Dyslipidemia, n(%)	103 (68.2)	83 (57.6)	.060
COPD, n(%)	30 (19.9)	25 (17.4)	.600
Peripheral vascular disease, n(%)	8 (5.3)	16 (11.1)	.068
Creatinine (mmol/L)	76 (68-97)	77 (68-93)	.857
Creatinine clearance (ml/min)			.632
≥ 90ml/min, n(%)	46 (30.5)	37 (25.7)	
60-89 ml/min, n(%)	59 (39.1)	67 (46.5)	
30-59 ml/min, n(%)	45 (29.8)	39 (27.1)	
<30 ml/min, n(%)	1 (0.7)	1 (0.7)	
Dialysis, n(%)	3 (1.99)	0	.248
EUROSCORE II (%)	1.25 (0.85-1.88)	1.35 (0.97-1.89)	.272
Atrial fibrillation, n(%)	21 (13.9)	19 (13.2)	.258
NYHA Class, n(%)			.105
I	6 (4.0)	7 (4.9)	
II	111 (73.5)	89 (61.8)	
III	34 (22.5)	47 (32.6)	
IV	0	1 (0.7)	

Hematocrit (%)	38.81 (± 4.66)	39.67 (± 3.84)	.088
LVEF (%)	64 (58-68)	65 (58-70)	.291
> 55, n(%)	130 (86.1)	125 (86.8)	
45-55, n(%)	12 (7.9)	14 (9.7)	.388
30-45, n(%)	9 (6.0)	4 (2.8)	
< 30, n(%)	0	1 (0.7)	
LVEDD (mm)	48.12 (±7.65)	48.14 (± 7.76)	.989
Aortic valve disease			
Stenosis, n(%)	52 (34.4)	49 (34.0)	
Regurgitation, n(%)	13 (8.6)	11 (7.6)	
Combined disease, n(%)	86 (57.0)	84 (58.3)	.945
Predominantly AS, n(%)	79 (91.9)	80 (95.2)	
Predominantly AR, n(%)	5 (5.8)	3 (3.6)	
Both severe AS and AR, n(%)	2 (2.3)	1 (1.2)	

AS: Aortic Stenosis, AR: Aortic Regurgitation, BMI: Body Mass Index, BSA: Body Surface Area, COPD: Chronical Obstructive Pulmonary Disease, DM: Diabetes Mellitus, LVEDD: Left Ventricular End-Diastolic Diameter, LVEF: Left Ventricular Ejection Fraction, NYHA: New York Heart Association

Table 2. Intraoperative characteristics

	Buckberg (n=151)	Del Nido (n=144)	p value
Total cardioplegia dose (ml)	374.5 (314-440)	1000 (1000-1000)	**< .001**
Total cardioplegia volume including blood content (ml)	1872.5 (1570-2200)	1250 (1250-1250)	
Cardioplegia route administration			**< .001**
Antegrade, n(%)	141 (93.38)	128 (88.89)	
Retrograde, n(%)	78 (51.66)	1 (0.69)	
Direct ostia cannulation, n(%)	75 (49.67)	22 (15.28)	
CPB time (min)	78 (64-97)	74 (61-92)	.245
Cross clamp time (min)	58 (45-73)	57.5 (44-69)	.524
Spontaneous rhythm after cross clamp remove, n(%)	65 (43.05)	96 (66.67)	**< .001**
Ventricular fibrillation requiring defibrillation, n(%)	75 (49.67)	34 (23.61)	**< .001**
Defibrillation attempts (n)	2.34 (±1.85)	2.03 (±1.66)	.293
Temporary pacemaker, n(%)	24 (15.89)	20 (13.89)	.629
LVEF			.790
> 55%, n(%)	132 (87.41)	131 (90.97)	
45-55%, n(%)	11 (7.38)	8 (5.56)	
30-45%, n(%)	7 (4.70)	4 (2.78)	
<30%, n(%)	1 (0.67)	1 (0.69)	
Dobutamine at CPB weaning, n(%)	19 (12.58)	14 (9.72)	.720
Low (<10μg/Kg/min), n(%)	16 (10.60)	12 (8.33)	
Moderate (10-15μg/Kg/min), n(%)	3 (1.99)	2 (1.39)	
High (>15μg/Kg/min), n(%)	0	0	
Norepinephrine at CBP weaning, n(%)	72 (47.68)	71 (49.31)	.954

Low (<0.03μg/Kg/min), n(%)	60 (39.74)	61 (42.36)	
Moderate (0.03-0.05μg/Kg/min), n(%)	10 (6.62)	9 (6.25)	
High (>0.05μg/Kg/min), n(%)	2 (1.32)	1 (0.69)	
Epinephrine at CBP weaning, n(%)	1 (0.66)	1 (0.69)	.739
Low (<0.05μg/Kg/min), n(%)	0 (0)	0 (0)	
Moderate (0.05-1μg/Kg/min), n(%)	1 (0.66)	0 (0)	
High (>1μg/Kg/min), n(%)	0 (0)	1 (0.69)	
IABP at CPB weaning, n(%)	1 (0.67)	1 (0.69)	.742
ECMO at CPB weaning, n(%)	2 (1.34)	0 (0)	.498
Cell saver use, n(%)	144 (96.64)	140 (97.22)	1
Cell saver volume (ml)	322.5 (250-440)	347.5 (250-469)	.229
Cell saver volume hematocrit (%)	45 (40-50)	45 (42.5-49)	.259
Ultrafiltration, n(%)	4 (2.68)	11 (7.64)	0.066
Minimal intraoperative hematocrit (%)	28.8 (25.7-32.3)	27.2 (24.95-29.95)	**.0045**
End of surgery hematocrit (%)	33.3 (30.4-36.6)	34 (31.1-37.6)	.175
Peak intraoperative lactate level (mmol/L)	1.1 (0.8-1.4)	1.1 (0.9-1.4)	.537
Peak intraoperative glucose level (mg/dl)	198 (176-228)	128 (111-156)	**< .001**
Intraoperative insulin needed, n(%)	77 (50.99)	27 (18.75)	**< .001**
Patients receiving red blood cells transfusion, n(%)	16 (10.6)	17 (11.81)	.773
Surgical approach			.611
Sternotomy, n(%)	113 (75.84)	104 (73.24)	
Upper mini-sternotomy, n(%)	36 (24.16)	38 (26.76)	

CPB: Cardiopulmonary Bypass, ECMO: Extracorporeal Membrane Oxygenation, IABP: Intraaortic Balloon Pump, LVEF: Left Ventricular Ejection Fraction

Table 3. Postoperative data

	Buckberg (n=153)	Del Nido (n=145)	p value
CK postoperative peak level (U/L)	430 (280-665)	414.5 (296-667)	.886
CK day 1 (U/L)	372 (249-550)	347 (241-520)	.570
CK day 2 (U/L)	329 (234-620)	361.5 (246-520)	.863
CK day 3 (U/L)	230 (144-482)	238 (149-394.5)	.977
CK day 4 (U/L)	135 (81-210.5)	125 (82-215)	.884
CK day 5 (U/L)	72 (49.5-117)	81 (49-133)	.840
TnT postoperative peak level (ng/L)	284 (197-547)	258 (183-450)	.255
TnT day 1 (ng/L)	257 (173-443)	237 (169-392)	.266
TnT day 2 (ng/L)	240 (162.5-405)	202 (149-369)	.151
TnT day 3 (ng/L)	201.5 (148-310)	176 (130.5-300)	.081
TnT day 4 (ng/L)	178 (136-273)	165 (118-269)	.319
TnT day 5 (ng/L)	167 (116-255)	139 (98.5-221.5)	.085
Postoperative dobutamine needed, n(%)	17 (11.11)	15 (10.34)	.217
Low (<10μg/Kg/min), n(%)	12 (7.84)	15 (10.34)	
Moderate (10-15μg/Kg/min), n(%)	2 (1.31)	0 (0)	
High (>15μg/Kg/min), n(%)	3 (1.96)	0 (0)	
Postoperative norepinephrine needed, n(%)	50 (32.68)	57 (39.31)	.0.71
Low (<0.03μg/Kg/min), n(%)	42 (27.45)	52 (35.86)	
Moderate (0.03-0.05μg/Kg/min), n(%)	3 (1.96)	5 (3.45)	
High (>0.05μg/Kg/min), n(%)	5 (3.27)	0 (0)	
Postoperative epinephrine needed, n(%)	4 (2.61)	0 (0)	.123
Low (<0.05μg/Kg/min), n(%)	0 (0)	0 (0)	
Moderate (0.05-1μg/Kg/min), n(%)	4 (2.61)	0 (0)	
High (>1μg/Kg/min), n(%)	0 (0)	0 (0)	

Postoperative IABP, n(%)	4 (2.61)	0 (0)	.123
Postoperative ECMO, n(%)	4 (3.27)	0 (0)	.123
Re-exploration for bleeding, n(%)	5 (3.27)	6 (4.14)	.767
Creatinine postoperative peak (mmol/L)	89.64 (74-134)	94 (73-125)	.954
AKIN stage 1, n(%)	17 (11.11)	15 (10.34)	
AKIN stage 2, n(%)	7 (4.56)	10 (6.90)	.753
AKIN stage 3, n(%)	11 (7.19)	5 (3.45)	
Renal replacement therapy, n(%)	5 (3.27)	0 (0)	.0.61
Patients receiving red blood cells transfusion, n(%)	38 (24.84)	31 (21.38)	.343
Hematocrit at discharge (%)	29 (27-32)	29.85 (27-32)	.494
LVEF (%)	59.5 (56-64)	60 (55-67)	.333
> 55, n(%)	124 (82.12)	119 (83.22)	
45-55, n(%)	22 (14.57)	14 (9.79)	.259
30-45, n(%)	7 (4.58)	12 (8.28)	
< 30, n(%)	0 (0)	0 (0)	
LVEDD (mm)	47.35 (±8.62)	46.86 (±7.78)	.633
ICU length of stay (d)	3 (2-4)	2 (2-4)	.075
In hospital stay (d)	7 (6-9)	7 (6-9)	.371
Operative mortality, n(%)	4 (2.65)	1 (0.69)	.123

AKIN: Acute Kidney Injury Network, CK: Creatine Kinase, ECMO: Extracorporeal Membrane Oxygenation, IABP: Intraaortic Balloon Pump, ICU: Intensive Care Unit, LVEDD: Left Ventricular End-Diastolic Diameter, LVEF: Left Ventricular Ejection Fraction, TnT: ultrasensitive Troponin T

Figure 1. Enrollment flow diagram.

Figure 2. CK and TnT postoperative levels

Figure 3. CK-TnT peak levels and cross-clamp time

Central image. Graphical abstract. Postoperative Ck and TnT peak levels

Figure 2





Figure 3









Bukcberg vs Del Nido in isolated aortic valve replacement: a prospective, multicentric, randomized trial

Summary

311 isolated AVR patients were randomized to BS or DNS in two different centers. Postoperative CK and TnT levels were determined. No differences in myocardial injury biomarkers were found. DNS group showed better glycemic control and less defibrillation after cross-clamp removal. No differences in haemodilution or red blood cell package transfusions were found.



Legend: AVR: aortic valve replacement, BS: Buckberg solution, DNS: Del Nido solution, CK: creatine kinase, TnT: ultrasensitive troponin T